- Direct factor Xa inhibitor rivaroxaban2009 | Faculty of Medicine in Hradec Králové
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study2008 | Faculty of Medicine in Hradec Králové
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study2008 | First Faculty of Medicine
- Anticoagulation 20132013 | Faculty of Medicine in Hradec Králové
- Edoxaban - medication profile2013 | Publication without faculty affiliation
- Novel anticoagulants in prevention of cardioembolic stroke in patiens with non-valvular atrial fibrillation2013 | First Faculty of Medicine
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty2008 | Central Library of Charles University
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty2008 | Central Library of Charles University
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty2008 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty2008 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- The pharmacological profile of apixaban2013 | First Faculty of Medicine, Third Faculty of Medicine
- Commentary on Aristotle study (Apixaban compared with warfarin in patients with atrial fibrillation)2011 | First Faculty of Medicine
- What we expect from anticoagulant therapy in 20142014 | Publication without faculty affiliation
- Comparison of new oral anticoagulants from the perspective of pharmacological features and clinical trials2013 | First Faculty of Medicine, Third Faculty of Medicine
- Position of rivaroxaban in current medicine2014 | Third Faculty of Medicine
- Where is a step in the current development of drugs that affect blood clotting?2012 | First Faculty of Medicine
- Apixaban in patients with atrial fibrillation and impaired renal function - subanalysis of ARISTOTLE study2013 | Publication without faculty affiliation
- Consensus recommendations for the prophylaxis of venous thrombosis after total joint replacement (TEP) of the hip or kneePublication without faculty affiliation
- Apixaban, a new oral antithrombotic agent - Review of marketing authorisation studies2012 | Second Faculty of Medicine
- New antithrombotics in the prevention of venous thromboembolia and new anti-platelet drugs2011 | Faculty of Medicine in Hradec Králové
- News in incidence and clinical mean of thrombophlebitis2012 | First Faculty of Medicine
- ARISTOTLE study - another milestone in anticoagulation therapy for atrial fibrillation2012 | Publication without faculty affiliation
- New anticoagulants in the prevention and treatment of cardiovascular diseases2010 | First Faculty of Medicine, Third Faculty of Medicine
- AMPLIFY-EXT study. Apixaban in the treatment of venous thromboembolism2013 | First Faculty of Medicine
- Guidelines of Czech Association for Thrombosis and Haemostasis of the Czech Medical Association of J. E. Purkyně for safety treatment with new oral anticoagulants (NOAC) - dabigatran etexilate, apixaban and rivaroxaban2015 | First Faculty of Medicine
- Dabigatran - clinical evidence for treatment in patients with thromboembolism2016 | First Faculty of Medicine
- Low molecular weight heparins - their significance in current practice2011 | Central Library of Charles University, Third Faculty of Medicine
- doplnit2011 | Faculty of Medicine in Hradec Králové
- Dabigatran in the prevention of stroke in patients with atrial fibrilation2011 | First Faculty of Medicine, Third Faculty of Medicine
- Will we change the strategy of anticoagulation therapy?2022 | Third Faculty of Medicine